Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Egetis Therapeutics

5.37 SEK

+0.19 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.19 %
+8.27 %
+0.56 %
+4.27 %
+7.94 %
+31.94 %
+4.27 %
-6.80 %
-61.19 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.28B SEK
Turnover
2.15M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.4
2026

Interim report Q1'26

6.5
2026

General meeting '26

21.8
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release11 hours ago

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Press release3/9/2026, 6:00 AM

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics
Press release3/5/2026, 9:56 AM

Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/2/2026, 4:10 PM

Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q4'25
Webcast2/26/2026, 9:00 AM

Egetis Therapeutics, Audiocast, Q4'25

Egetis Therapeutics
Regulatory press release2/26/2026, 6:00 AM

Year-End Report January-December 2025

Egetis Therapeutics
Press release2/24/2026, 10:00 AM

Egetis Therapeutics to Present at Upcoming Investor Events

Egetis Therapeutics
Press release2/19/2026, 9:30 AM

Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026

Egetis Therapeutics
Press release2/16/2026, 6:00 AM

Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan

Egetis Therapeutics
Press release2/4/2026, 2:25 PM

FDA's rare pediatric disease priority review program extended until 2029

Egetis Therapeutics
Regulatory press release1/29/2026, 6:00 AM

Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

Egetis Therapeutics
Press release1/16/2026, 11:45 AM

Chairman of the Board of Egetis Therapeutics acquires shares

Egetis Therapeutics
Press release1/8/2026, 8:30 AM

Egetis Therapeutics to Host Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Egetis Therapeutics
Regulatory press release12/30/2025, 7:00 AM

Change in the number of ordinary shares and votes in Egetis Therapeutics

Egetis Therapeutics
Regulatory press release12/19/2025, 6:00 AM

Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency

Egetis Therapeutics
Press release12/17/2025, 12:35 PM

Egetis Therapeutics to move to the Nasdaq Stockholm Mid Cap segment

Egetis Therapeutics
Press release12/10/2025, 6:00 AM

Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe

Egetis Therapeutics
Press release12/4/2025, 9:55 AM

New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta

Egetis Therapeutics
Press release12/1/2025, 10:15 AM

Members of Egetis' Leadership Team acquire shares in Egetis

Egetis Therapeutics
Press release11/27/2025, 1:07 PM

Redeye: Egetis (Q3 review) - Focus on US application

Egetis Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.